Giant Cell Arteritis: The Place of 18F-FDG PET/CT and Serum Haptoglobin Level
(2022) Mayo Clinic Proceedings — Vol. 97, n° 1, p. 189 (2022)
Files
1-s20-S0025619621008673-main.pdf
Open Access - Adobe PDF
- 112.75 KB
Details
- Authors
- Abstract
- (en) TO THE EDITOR, I read with great interest the article by Garvey et al. They mentioned that treatment with tocilizumab induced a direct inhibition of the acute phase response, and thus C-reactive protein levels are difficult to interpret. This is why identifying active disease or relapse is a challenge in these patients. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has been proposed as a useful tool to assess response and relapse. However, several studies reported that a complete normalization of PET/CT activity occurred in less than 30% of patients while they are in clinical remission. [...]
- Affiliations
Citations
Yildiz, H. (2022). Giant Cell Arteritis: The Place of 18F-FDG PET/CT and Serum Haptoglobin Level. Mayo Clinic Proceedings, 97(1), 189. https://doi.org/10.1016/j.mayocp.2021.11.016 (Original work published 2022)